Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Plug Power Inc (PLUG) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

PLUG trades at $2.23, down 6.3% on the day, with a bearish technical signal and negative cash flows. The company reported a net loss of $1.63 billion in 2025 despite revenue of $710 million, with gross profit margin at -25.66%. Recent news includes a 50MW electrolyzer order for the Hunter Valley Hydrogen Hub in Australia, but the stock faces pressure from analyst target cuts and high short interest of 27.4%.

Outlook remains challenged by persistent losses and cash burn, though analyst consensus suggests 31% upside to the $2.92 target. Key risks include delayed profitability targets beyond 2028 and reliance on financing amid negative operating cash flow. The stock's viability hinges on successful project execution and hydrogen market adoption.